Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Cerilliant
Boehringer Ingelheim
Argus Health
Farmers Insurance
Fish and Richardson
Medtronic
Dow

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,743,413

« Back to Dashboard

Which drugs does patent 6,743,413 protect, and when does it expire?

Patent 6,743,413 protects FLOVENT HFA and is included in one NDA.

Protection for FLOVENT HFA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-six patent family members in twelve countries.
Summary for Patent: 6,743,413
Title: Suspension aerosol formulations
Abstract:Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
Inventor(s): Schultz; Robert K. (Shoreview, MN), Schultz; David W. (Pine Springs, MN), Oliver; Martin J. (Loughborough, GB), Moris; Robert A. (Lino Lakes, MN), Jinks; Philip A. (Mount Sorrel, GB)
Assignee: 3M Company (St. Paul, MN)
Application Number:08/455,280
Patent Claim Types:
see list of patent claims
Formulation; Delivery; Use;

Drugs Protected by US Patent 6,743,413

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-002 May 14, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,743,413

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,101,534 Suspension aerosol formulations ➤ Sign Up
7,105,152 Suspension aerosol formulations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Cantor Fitzgerald
US Army
US Department of Justice
AstraZeneca
Teva
Fuji
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.